It is considered unlikely to be important in the context of co-administered oral medications but may have contributed to the observed reductions in postprandial glucose
Overall rates of major birth defects (2.6%) were similar to diabetic (2.3%) and obese (3.9%) control groups
Pusch W, Wurmbach JH, Thiele H, Kostrzewa M
Semaglutide: Linear polypeptide PEPTIDE SEQUENCE Cagrilintide: ?Glu-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH 2 Semaglutide: H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CHEMICAL STRUCTURE Cagrilintide: Semaglutide: CHEMICAL STRUCTURE Cagrilintide: C 194 H 312 N 54 O 59 S 2 Semaglutide: C 187 H 291 N 45 O 59 Mechanism of Action Cagrilintide acts primarily as a long-acting amylin analogue, stimulating amylin and calcitonin receptors to promote satiety, slow gastric emptying, and suppress postprandial glucagon release
GLP-1 medications like semaglutide have a 7-day half-life, meaning trace amounts remain in your system for 3 to 4 weeks
doi: 10.1016/0024-3205(93)90589-u
